RISK OF DEATH AFTER PACLITAXEL EXPOSURE DURING FEMOROPOPLITEAL ARTERY ANGIOPLASTY – NARRATIVE REVIEW

Detalhes bibliográficos
Autor(a) principal: F. Ribeiro, Tiago
Data de Publicação: 2022
Outros Autores: Ferreira, Rita Soares, Cardoso, Joana, Figueiredo, Adriana, Fidalgo, Helena, Gonçalves, Frederico Bastos, Ferreira, Maria Emília
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: https://doi.org/10.48750/acv.436
Resumo: Paclitaxel molecule has been on the market since 1991 and is indicated for the treatment of multiple neoplasms. Since 2012 has been used in endovascular devices for the treatment of peripheral artery disease and have become a mainstay in the treatment of symptomatic femoro-popliteal lesions, in particular for preventing arterial restenosis. They have a proven benefit in patency and freedom-from re-intervention up to 5 years. A recent meta-analysis of RCT showed an increased late-mortality rate, however, real-life cohorts analyses presents contradictory results. RCT meta-analysis is comprised mainly by claudicants, and CLTI patients are underrepresented. Further studies are needed to clarify this matter, in particular with a higher percentage of CLTI presentation. For now, patients should be advised about risks and benefits of paclitaxel exposure and a shared decision-making process should be followed.
id RCAP_c782bb1bc176b47f90c6f62a1229ea0a
oai_identifier_str oai:ojs.acvjournal.com:article/436
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling RISK OF DEATH AFTER PACLITAXEL EXPOSURE DURING FEMOROPOPLITEAL ARTERY ANGIOPLASTY – NARRATIVE REVIEWRISCO DE MORTE APÓS EXPOSIÇÃO A PACLITAXEL DURANTE ANGIOPLASTIA DAS ARTÉRIAS FEMORAL E POPLITEIA – REVISÃO NARRATIVAPeripheral Artery DiseaseEndovascular TherapyPaclitaxel Coated DevicesDoença Arterial PeriféricaTratamento EndovascularDispositivos revestidos com PaclitaxelPaclitaxel molecule has been on the market since 1991 and is indicated for the treatment of multiple neoplasms. Since 2012 has been used in endovascular devices for the treatment of peripheral artery disease and have become a mainstay in the treatment of symptomatic femoro-popliteal lesions, in particular for preventing arterial restenosis. They have a proven benefit in patency and freedom-from re-intervention up to 5 years. A recent meta-analysis of RCT showed an increased late-mortality rate, however, real-life cohorts analyses presents contradictory results. RCT meta-analysis is comprised mainly by claudicants, and CLTI patients are underrepresented. Further studies are needed to clarify this matter, in particular with a higher percentage of CLTI presentation. For now, patients should be advised about risks and benefits of paclitaxel exposure and a shared decision-making process should be followed.A molécula paclitaxel está disponível no mercado desde 1991 e está indicada no tratamento de diversas neoplasias. A partir de 2012, a sua utilização foi expandida para dispositivos endovasculares para o tratamento da doença arterial periférica, apresentando-se hoje como uma das principais escolhas no tratamento de lesões arteriais femoro-popli- teias sintomáticas, especialmente pelo seu benefício na prevenção de re-estenoses. Estes dispositivos apresentam atualmente um benefício comprovado na sobrevida livre de re-intervenção e permeabilidade até 5 anos. Uma meta- -análise de estudos randomizados revelou um aumento na mortalidade a longo-prazo, no entanto, estudos de coorte com populações mais representativas da prática clinica diária, apresentam resultados discordantes. Salienta-se o facto desta meta-análise ser composta predominantemente por doentes claudicantes, estando os doentes com isquemia crónica com risco de perda de membro sub-representados. Estudos concebidos especificamente para este intuito são necessários para esclarecer este tópico. Por enquanto, os doentes deverão ser alertados para os eventuais riscos e benefícios da exposição a paclitaxel e um processo de decisão conjunta deverá ser um objetivo.Sociedade Portuguesa de Angiologia e Cirurgia Vascular2022-03-02T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttps://doi.org/10.48750/acv.436oai:ojs.acvjournal.com:article/436Angiologia e Cirurgia Vascular; Vol. 17 No. 4 (2021): December; 313-317Angiologia e Cirurgia Vascular; Vol. 17 N.º 4 (2021): Dezembro; 313-3172183-00961646-706Xreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAPenghttp://acvjournal.com/index.php/acv/article/view/436https://doi.org/10.48750/acv.436http://acvjournal.com/index.php/acv/article/view/436/272Copyright (c) 2022 Angiologia e Cirurgia Vascularinfo:eu-repo/semantics/openAccessF. Ribeiro, TiagoFerreira, Rita SoaresCardoso, JoanaFigueiredo, AdrianaFidalgo, HelenaGonçalves, Frederico BastosFerreira, Maria Emília2022-05-23T15:10:14Zoai:ojs.acvjournal.com:article/436Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T14:57:45.986092Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv RISK OF DEATH AFTER PACLITAXEL EXPOSURE DURING FEMOROPOPLITEAL ARTERY ANGIOPLASTY – NARRATIVE REVIEW
RISCO DE MORTE APÓS EXPOSIÇÃO A PACLITAXEL DURANTE ANGIOPLASTIA DAS ARTÉRIAS FEMORAL E POPLITEIA – REVISÃO NARRATIVA
title RISK OF DEATH AFTER PACLITAXEL EXPOSURE DURING FEMOROPOPLITEAL ARTERY ANGIOPLASTY – NARRATIVE REVIEW
spellingShingle RISK OF DEATH AFTER PACLITAXEL EXPOSURE DURING FEMOROPOPLITEAL ARTERY ANGIOPLASTY – NARRATIVE REVIEW
F. Ribeiro, Tiago
Peripheral Artery Disease
Endovascular Therapy
Paclitaxel Coated Devices
Doença Arterial Periférica
Tratamento Endovascular
Dispositivos revestidos com Paclitaxel
title_short RISK OF DEATH AFTER PACLITAXEL EXPOSURE DURING FEMOROPOPLITEAL ARTERY ANGIOPLASTY – NARRATIVE REVIEW
title_full RISK OF DEATH AFTER PACLITAXEL EXPOSURE DURING FEMOROPOPLITEAL ARTERY ANGIOPLASTY – NARRATIVE REVIEW
title_fullStr RISK OF DEATH AFTER PACLITAXEL EXPOSURE DURING FEMOROPOPLITEAL ARTERY ANGIOPLASTY – NARRATIVE REVIEW
title_full_unstemmed RISK OF DEATH AFTER PACLITAXEL EXPOSURE DURING FEMOROPOPLITEAL ARTERY ANGIOPLASTY – NARRATIVE REVIEW
title_sort RISK OF DEATH AFTER PACLITAXEL EXPOSURE DURING FEMOROPOPLITEAL ARTERY ANGIOPLASTY – NARRATIVE REVIEW
author F. Ribeiro, Tiago
author_facet F. Ribeiro, Tiago
Ferreira, Rita Soares
Cardoso, Joana
Figueiredo, Adriana
Fidalgo, Helena
Gonçalves, Frederico Bastos
Ferreira, Maria Emília
author_role author
author2 Ferreira, Rita Soares
Cardoso, Joana
Figueiredo, Adriana
Fidalgo, Helena
Gonçalves, Frederico Bastos
Ferreira, Maria Emília
author2_role author
author
author
author
author
author
dc.contributor.author.fl_str_mv F. Ribeiro, Tiago
Ferreira, Rita Soares
Cardoso, Joana
Figueiredo, Adriana
Fidalgo, Helena
Gonçalves, Frederico Bastos
Ferreira, Maria Emília
dc.subject.por.fl_str_mv Peripheral Artery Disease
Endovascular Therapy
Paclitaxel Coated Devices
Doença Arterial Periférica
Tratamento Endovascular
Dispositivos revestidos com Paclitaxel
topic Peripheral Artery Disease
Endovascular Therapy
Paclitaxel Coated Devices
Doença Arterial Periférica
Tratamento Endovascular
Dispositivos revestidos com Paclitaxel
description Paclitaxel molecule has been on the market since 1991 and is indicated for the treatment of multiple neoplasms. Since 2012 has been used in endovascular devices for the treatment of peripheral artery disease and have become a mainstay in the treatment of symptomatic femoro-popliteal lesions, in particular for preventing arterial restenosis. They have a proven benefit in patency and freedom-from re-intervention up to 5 years. A recent meta-analysis of RCT showed an increased late-mortality rate, however, real-life cohorts analyses presents contradictory results. RCT meta-analysis is comprised mainly by claudicants, and CLTI patients are underrepresented. Further studies are needed to clarify this matter, in particular with a higher percentage of CLTI presentation. For now, patients should be advised about risks and benefits of paclitaxel exposure and a shared decision-making process should be followed.
publishDate 2022
dc.date.none.fl_str_mv 2022-03-02T00:00:00Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://doi.org/10.48750/acv.436
oai:ojs.acvjournal.com:article/436
url https://doi.org/10.48750/acv.436
identifier_str_mv oai:ojs.acvjournal.com:article/436
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv http://acvjournal.com/index.php/acv/article/view/436
https://doi.org/10.48750/acv.436
http://acvjournal.com/index.php/acv/article/view/436/272
dc.rights.driver.fl_str_mv Copyright (c) 2022 Angiologia e Cirurgia Vascular
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Copyright (c) 2022 Angiologia e Cirurgia Vascular
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Sociedade Portuguesa de Angiologia e Cirurgia Vascular
publisher.none.fl_str_mv Sociedade Portuguesa de Angiologia e Cirurgia Vascular
dc.source.none.fl_str_mv Angiologia e Cirurgia Vascular; Vol. 17 No. 4 (2021): December; 313-317
Angiologia e Cirurgia Vascular; Vol. 17 N.º 4 (2021): Dezembro; 313-317
2183-0096
1646-706X
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799129850704822272

Registros relacionados